US20060003083A1 - Food containing glycine and use thereof - Google Patents

Food containing glycine and use thereof Download PDF

Info

Publication number
US20060003083A1
US20060003083A1 US11/165,200 US16520005A US2006003083A1 US 20060003083 A1 US20060003083 A1 US 20060003083A1 US 16520005 A US16520005 A US 16520005A US 2006003083 A1 US2006003083 A1 US 2006003083A1
Authority
US
United States
Prior art keywords
glycine
food
sleep
substance
hydrolyzed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US11/165,200
Other versions
US10561629B2 (en
Inventor
Tohru Kouda
Chika Morishima
Kentaro Inagawa
Shinobu Seki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34797738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060003083(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Assigned to AJINOMOTO CO., INC. reassignment AJINOMOTO CO., INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KOUDA, TOHRU, MORISHIMA, CHIKA, INAGAWA, KENTARO, SEKI, SHINOBU
Publication of US20060003083A1 publication Critical patent/US20060003083A1/en
Application granted granted Critical
Publication of US10561629B2 publication Critical patent/US10561629B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/44Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing peptides or proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A23L5/20Removal of unwanted matter, e.g. deodorisation or detoxification
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L9/00Puddings; Cream substitutes; Preparation or treatment thereof
    • A23L9/10Puddings; Dry powder puddings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a food containing glycine and use thereof.
  • Glycine is a non-essential amino acid having the simplest structure of CH 2 (NH 2 )COOH.
  • Glycine is an amino acid approved as a food additive and contained in many foods.
  • beverages contain glycine at a maximum content of about 50 mg/100 ml for the preservation of quality.
  • glycine is also contained in fish cake products such as steamed fish paste and the like.
  • As a known function of glycine its intake at 0.1 g per day increases memory and attention (see, File. S. E. et al., Journal of Clinical Psychopharmacology. US, 1999, vol. 19, No. 6, pp. 506-512).
  • addition of glycine as an antispoilage agent for food together with maltose is known (see, JP-B-2-72853), in which case the amount of glycine to be added is, for example, about 0.3% (W/W).
  • the present invention provides:
  • a food of the type based on unit of intake per serving which contains glycine or a substance that can be hydrolyzed to give glycine, in an amount equivalent to not less than 0.5 g of glycine per serving.
  • the food of the above-mentioned (1) or (2), wherein the glycine or the substance that can be hydrolyzed to give glycine is a powder or a granule.
  • a food for improving a deep sleep disorder which contains glycine or a substance that can be hydrolyzed to give glycine.
  • a food for improving bowel movements which contains glycine or a substance that can be hydrolyzed to give glycine.
  • a method of masking a flavor of a food material itself or a flavor imparted by food processing which comprises adding 0.15-100% by weight of glycine relative to the food as a whole.
  • a method of improving a deep sleep disorder which comprises taking a food containing glycine or a substance that can be hydrolyzed to give glycine.
  • a method of improving bowel movements which comprises taking a food containing glycine or a substance that can be hydrolyzed to give glycine.
  • a commercial package comprising a food containing glycine or a substance that can be hydrolyzed to give glycine, and a written matter containing an explanation relating to use thereof for masking a flavor of a food material itself or a flavor imparted by food processing.
  • a commercial package comprising a food containing glycine or a substance that can be hydrolyzed to give glycine, and a written matter containing an explanation relating to use thereof for improving a deep sleep disorder.
  • a commercial package comprising a food containing glycine or a substance that can be hydrolyzed to give glycine, and a written matter containing an explanation relating to use thereof for improving bowel movements.
  • FIG. 1 is shows glycine intake and sleep hours during a trip to the East Coast, USA, by the test participant (Experimental Example 2);
  • FIG. 2 is a graph showing the relationship between the lapse of time after glycine administration and R-R interval in a test using beagles (Experimental Example 7).
  • glycine is an amino acid having the structure of CH 2 (NH 2 )COOH.
  • the “substance that can be hydrolyzed to give glycine” is a substance that affords glycine by hydrolysis (particularly hydrolysis in vivo). Representative examples thereof include proteins and peptides having glycine as a constituent unit.
  • a substance that affords glycine by hydrolysis is expected to provide the same effect as that achieved by direct glycine intake, as a result of generation of glycine due to hydrolysis in the body after the intake.
  • the food of the type based on unit of intake per serving in the present invention contains glycine or a substance that can be hydrolyzed to give glycine in an amount equivalent to not less than 0.5 g of glycine per serving. Since such a food permits easy intake of a large amount of glycine, it allows enjoyment of effects provided by the below-mentioned novel action.
  • the “food of the type based on unit of intake per serving” includes foods having a predetermined amount of intake per serving.
  • food is a concept broadly encompassing those that can be taken orally (excluding pharmaceutical products), and includes what is called “foods”, as well as beverages, health aid foods, healthcare functional foods, supplements, and the like.
  • the unit of intake per serving in the case of, for example, beverage, candy, chewing gum, jelly, pudding, yoghurt and the like, is a pack, a packing, a bottle and the like that define a given amount, and that in the case of a granular, powdery or slurry food is a packing and the like that define a given amount, or a container and the like that indicate the amount of intake per serving.
  • the content of glycine or a substance that can be hydrolyzed to give glycine per serving is not less than 0.5 g, preferably not less than 1.0 g, more preferably not less than 1.5 g, when converted to the amount of glycine, in view of ease of addition to the food and the effect of the addition.
  • the above-mentioned content is preferably not more than 100 g, more preferably not more than 60 g, from eating experience based on known findings (see, Evins A. E. et al., American Journal of Psychiatry, US, May 2000, vol. 157, No. 5, pp. 826-828) and ease of packing and intake.
  • the present inventors have also found that the presence of a large amount of one or more amino acids other than glycine in the above-mentioned food tends to prevent the benefit of the below-mentioned effects. Therefore, the total content of any amino acids other than glycine or a substance that can be hydrolyzed to give an amino acid other than glycine is preferably equivalent to not more than 5 g of the amino acids other than glycine per serving.
  • the amino acid other than glycine refers to amino acids other than the above-mentioned glycine.
  • amino acid is meant an organic compound having both an amino group (—NH 2 ) and a carboxyl group (—COOH).
  • the “substance that can be hydrolyzed to give an amino acid other than glycine” is a substance affording an organic compound (except for glycine) having both an amino group and a carboxyl group by hydrolysis (particularly hydrolysis in vivo), and typical examples include proteins and peptides having an amino acid other than glycine as a constituent element can be mentioned.
  • the shape or form of the glycine or a substance that can be hydrolyzed to give glycine contained in a food is not particularly limited and may be a powder or granule, as well as slurry, tablet, capsule, solution, gel, or emulsion. Of these, granules and powder are preferable for portability and ease of packing. In addition, solution, gel and slurry are also preferable because of the ease of intake.
  • the “slurry” glycine contained in food means a state where solid glycine is suspended in a liquid media. A part of glycine may be dissolved in the above-mentioned media.
  • not less than 0.5 g of granular glycine may be packed in an intake unit amount and the like.
  • a drink containing not less than 0.5 g of glycine in a suspension or solution is placed in a bottle etc. sized for one meal or serving.
  • the type of food is not particularly limited and application to various foods is possible. Since glycine has a high solubility in water and has preferable sweetness, it can be suitably applied to beverages, confectioneries, jellies, puddings, and yoghurt. Beverages may be served in a bottle, a can, a paper pack and the like in the form of a solution, a suspension and the like, or may be extracted or dissolved for drinking like tea, coffee, powder beverage and the like. As used herein, by confectionery is meant favorite food taken besides meals, such as sweets and the like (e.g., candy, chewing gum, tablet and the like).
  • mammals such as domestic animal, fowl and the like, experimental animals and the like can be mentioned.
  • the mode of administration to animals other than human may be as an addition to a diet.
  • the invention relating to the novel use of glycine is explained in the following.
  • the novel use of the present invention refers to the use as food flavoring, arousal during sleep and early-morning awakening suppressing food, deep sleep disorder improving food or bowel movement improving food.
  • amino acids have been generally used as a reaction flavor under special conditions of industrial environment at high temperature.
  • the present inventors have found that a preferable flavor can be produced upon reaction with sugars contained in the food under conditions that can be generally produced at home, such as addition of boiled water to glycine and the like.
  • glycine can be used for masking of undesirable flavor in the food.
  • the food flavoring in the present invention is a concept expressing a substance that adds flavor to a food material having almost no flavor, enforcing the flavor lost during production of food, masking an unpreferable flavor which a food material itself has or which is produced during processing.
  • glycine For use as a food flavoring, glycine only needs to be added to a food.
  • the glycine content can be appropriately determined according to the amount of the flavor to be added and the level of masking to be performed.
  • glycine is added in an amount of preferably 0.5 to 100 g, more preferably 1.0 to 60 g, per serving.
  • the weight of glycine in the whole food is preferably 0.15 to 100 wt %, more preferably 0.3 to 98 wt %, in consideration of solubility, preferable taste, and effectiveness of flavor and masking.
  • a preferable mode of use for this purpose is, for example, allowing reaction with sugars by heating, such as addition of boiling water and the like.
  • sugars to be reacted sucrose, fructose, glucose, dextrin, maltose and the like can be mentioned.
  • the present invention also encompasses a method of masking a flavor of a food material itself or a flavor imparted by food processing, which comprises adding glycine in a proportion of 0.15 to 100% by weight, preferably 0.3 to 98 wt %, of the whole food.
  • the “unpreferable flavor” in a food for which glycine is used for masking includes flavors of medicinal plants used for crude drugs and Chinese herbal medicines, yacon, Eucommia ulmoides, and Puer contained in general health food and the like, plant extracts such as Houttuynia cordata used for folk remedies and the like, and herbs generally taken as herb or extracted for drinking.
  • Another aspect of the present invention is use of a food containing glycine (or a substance that can be hydrolyzed to give glycine) as a deep sleep disorder improving food.
  • deep sleep disorder is meant a condition lacking satisfaction from deep sleep on awakening, or a condition of shortage of sleep, or a condition lacking satisfaction in various aspects expected to be afforded by a suitable sleep.
  • such conditions includes shallow sleep, difficult shift to slow wave sleep indicating profound sleep after sleep onset, interrupted sleep, failure to get up at expected time and insufficient sleep hours, and is considered to often occur in an unsuitable sleep environment, in the presence of mental or physical stress, after intake of an ingredient having an awakening effect such as caffeine and the like before bedtime, at the time of excessive drinking, irregular sleep cycles and disturbed biological rhythm, as well as in a time lag environment.
  • a deep sleep disorder improving food is effective not only for improving the above-mentioned deep sleep disorder but also allowing the inherent role of sleep to be fulfilled by improving the quality of sleep. Such a role includes, for example, affording the feeling of being refreshed on rising, decreasing lassitude, preventing tendency of oversleeping during the daytime and the like.
  • a deep sleep disorder improving food can improve the above-mentioned deep sleep disorders.
  • the concept represented by what is called a “sleep disorder” and “insomnia” is also included in the concept of the aforementioned “deep sleep disorder”.
  • the food of the present invention as a deep sleep disorder improving food contains glycine or a substance that can be hydrolyzed to give glycine.
  • the amount of intake of the aforementioned food for this purpose is preferably 0.00625 to 2.5 g/kg/day, more preferably 0.125 to 1.5 g/kg/day (daily intake per 1 kg of body weight), in an amount equivalent to glycine.
  • the term “equivalent to glycine” has the same meaning as mentioned above. An amount not less than the lower limit of the aforementioned numerical range is sufficient to afford the aforementioned effect. When the amount of intake is increased, the intake tends to be come difficult, and the cost becomes high.
  • a food of the aforementioned type based on the unit of intake per serving facilitates control of the amount of intake of glycine.
  • Glycine is considered to induce shift to slow wave sleep (deep sleep), improves the quality of sleep during sleep hours, appropriately controls visceral activity during sleep and encourages natural sleep by allowing dominant action on parasympathetic that acts opposite to sympathetic dominant.
  • glycine is taken for such use relating to sleep, it is most suitably taken before going to bed.
  • an arousal during sleep suppressing food and an early-morning awakening suppressing food can be mentioned.
  • the term “arousal during sleep” means waking up at night and being unable to go back to sleep for a while thereafter and by the “early-morning awakening” is meant waking up earlier than intended and being unable to go back to sleep again.
  • An arousal during sleep or early-morning awakening suppressing food can improve at least one condition of the above-mentioned arousal during sleep and early-morning awakening.
  • the food of the present invention as an arousal during sleep or early-morning awakening suppressing food contains glycine or a substance that can be hydrolyzed to give glycine.
  • the preferable amount of intake of the aforementioned food for this purpose is the same as that of a deep sleep disorder improving food.
  • Another embodiment of the present invention is use of a food containing glycine (or a substance that can be hydrolyzed to give glycine) as a bowel movement improving food.
  • bowel movement improving is meant a food capable of improving abnormal bowel movements (ie., constipation and diarrhea).
  • a food containing glycine or a substance that can be hydrolyzed to give glycine only needs to be taken.
  • the preferable amount of intake of the aforementioned food for this purpose is the same as that of a deep sleep disorder improving food.
  • the written material is, for example, what is called a package insert describing items relating to use, efficacy, drinking/eating method and the like, and the like.
  • Glycine powder (substantially pure, 2 g) was added to commercially available tea bags of the blend tea shown in Table 1 and the same tea bags without the addition were also prepared. A given amount (150 ml) of hot water was added and the tea was extracted for 1 minute. Five test participants drank the extracted blend tea and commented as to the decrease of flavor by the addition of glycine as compared to non-addition of glycine. The decrease of flavor was taken as an index of the masking effect (see, Table 1). The majority of the test participants confirmed the masking effect in all three kinds of the tested blend tea, and most of them found it to be a preferable masking effect.
  • FIG. 1 The glycine intake and sleep hours when a Japanese test participant living in Japan (male, 44 years old, body weight 62 kg) traveled to the East Coast, USA, are shown in FIG. 1 .
  • glycine substantially pure tablet glycine containing only excipient and flavor
  • This test participant frequently woke up during sleep in previous similar trips, but as is clear from the results of FIG. 1 , administration of glycine reduced or eliminated arousal during sleep.
  • test participants Three test participants (test participants A-C, body weight 64-74 kg) who were then visiting the U.S. for 5 days took glycine (1.5 g, substantially pure tablet glycine containing only excipient and flavor) before sleep and evaluated the sleepiness felt from 1 pm to 5 pm the next afternoon in 3 levels as compared to the absence of glycine.
  • glycine 1.5 g, substantially pure tablet glycine containing only excipient and flavor
  • the test participant (body weight 45 kg) took, before going to bed, 3 g of glycine directly or upon addition to various foods (see, Table 3).
  • the content (amount based on amino acid) of an amino acid other than glycine or a substance that can be hydrolyzed to give an amino acid other than glycine in these foods was generally 0 to 4 g.
  • easiness of falling asleep and realization of deep sleep upon waking the next morning were recorded and summarized in Table 3.
  • the test participants (body weight 45-80 kg) took 3 g of glycine (substantially pure glycine granule and powder) as it was, or after dissolving or suspending in water, juice, sport beverage and the like, or after addition to jelly, pudding and the like and then slept, after which they voluntarily commented on the quality of sleep as compared to the absence of intake.
  • glycine substantially pure glycine granule and powder
  • test participant A body weight 52 kg
  • B body weight 45 kg
  • glycine substantially pure tablet glycine containing only excipient and flavor
  • Table 5 reports the bowel movements on the next morning and the corresponding number of days. When glycine was taken before going to bed, the bowel movements in the next morning increased. When taken together with yoghurt, the bowel movements were also improved.
  • Glycine substantially pure glycine powder
  • CTRL control, CTRL
  • the R-R interval in electrocardiogram was measured by a telemetry system as an index of sympathetic activity. The measurement was conducted in the night after glycine administration. From the R-R interval after oral administration of glycine, moreover, sympathetic activity ((low frequency component LF)/(high frequency component HF)) and parasympathetic activity (high frequency component HF) were examined by power spectrum analysis.
  • FIG. 2 shows the relationship between the lapse of time after administration and the R-R interval.
  • the test participant A (body weight 45 kg) took glycine (substantially pure powder) in an amount shown in Table 6 before going to bed by dissolving same in water, and recorded the level of realization of deep sleep.
  • “+” was marked
  • “ ⁇ ” was marked
  • “ ⁇ ” was marked and when it became worse, “ ⁇ ” was marked.
  • Table 6 The results are shown in Table 6.
  • a double-blind crossover test aiming at confirmation of the effect of glycine on sleep was performed with 15 female adults (20s -50s, body weight 46-58 kg).
  • the test participants took glycine (granule containing citric acid and the like) in an amount equivalent to 3 g of glycine 1 hr before bedtime, and reduced maltose containing components other than glycine (citric acid and the like) and adjusted to an almost indistinguishable taste was used as a placebo.
  • glycine and placebo were each taken for 4 days with an interval of a 3 day non-intake period, totaling 2 weeks.
  • test participants of 32 years old or older (6 out of 15 participants, body weight 46-58 kg) significantly showed an effect of improving physical conditions on waking (good physical shape, lethargic feeling, heavy-headed feeling and the like) and mental conditions on waking (refreshed feeling, sick feeling and the like), and the test participant having problems regarding sleep (7 out of 15 participants, body weight 46-58 kg) who marked 9 points or more in the Pittsburgh Sleep Quality Index (PSQI) significantly showed an effect of improving mental conditions on waking.
  • PSQI Pittsburgh Sleep Quality Index
  • a double-blind crossover test aiming at confirmation of the effect of glycine on sleep was performed with 14 male adults (body weight 64-112.5 kg, average 81.2 kg) concerned about snoring and apnea condition during sleep.
  • the test participants took glycine (granules containing citric acid and the like) in an amount equivalent to 3 g of glycine 1 hr before bedtime, and reduced maltose containing components other than glycine (citric acid and the like) and adjusted to an almost indistinguishable taste was used as a placebo.
  • the slow wave sleep (%) in early stage of sleep onset in the Table shows a test participant average of the ratio of slow wave sleep to the early stage (1 hr) of sleep onset.
  • Glycine substantially pure glycine powder was administered to rats at 0 g/kg and 2 g/kg (0 g/kg for control) and using the rat, spontaneous electroencephalogram and cervix electromyogram were recorded through an electrode placed in the cortex hippocampus, and further, the amount of spontaneous motor activity was measured by an infrared ray monitor.
  • the sleep-wake cycle was analyzed from the electroencephalogram, electromyogram and behavior record (kymogram), and percent occupation of light period and dark period and latency time were calculated. Table 12 shows percent occupation of sleep-wake cycle at every 3 hours, Table 13 shows latency time and Table 14 shows the amount of spontaneous motor activity at 6 hours after administration (all in mean ⁇ standard error).
  • a single-blind crossover study aimed at confirmation of the effect of glycine on sleep was performed with 7 male adults (30s -40s, body weight 62-79 kg).
  • the test participants took glycine (granule containing citric acid and the like) in an amount equivalent to 3 g of glycine 30 min before bedtime, and reduced maltose containing components other than glycine (citric acid and the like) and adjusted to an almost indistinguishable taste was used as a placebo.
  • the sleep hours on the day of administration was limited to about 75% (5-6.5 hr) of comfortable sleep hours each test participant voluntarily notified, and a nap was prohibited until the end of the administration.
  • glycine and placebo were each taken for 3 days with an interval of a 14-21 day non-intake period, totaling 4-5 weeks. Of the 3 days, the following investigation and measurement were performed at 10 o'clock, 14 o'clock and 18 o'clock of the next day of the first day of the intake.
  • the p value is a statistical value showing the probability when the difference between glycine and placebo was hypothesized to be null. Particularly, this value of 0.05 or below is considered to indicate a significant difference. It was shown that glycine improved physical and mental conditions such as daytime lassitude and sleepiness of the next day by improving the sleep conditions.
  • the food of the present invention can provide a masking effect of an unpreferable flavor, a deep sleep disorder improving effect, such as an arousal during sleep suppressing effect and an early-morning awakening suppressing effect, a bowel movement improving effect and the like.
  • a food of the type based on the unit intake of the present invention can easily enjoy the effect afforded by the above-mentioned action.

Abstract

The present invention provides a food of the type based on unit of intake per serving, which contains glycine or a substance that can be hydrolyzed to give glycine in an amount of not less than 0.5 g based on glycine per serving. The food of the present invention can be applied as a food flavoring, a deep sleep disorder improving food, or a bowel movement improving food.

Description

    CROSS REFERENCES TO RELATED APPLICATIONS
  • This application is a continuation-in-part, of International Patent Application No. PCT/JP2004/019771, filed on Dec. 24, 2004, and claims priority to Japanese Patent Application No. 2004-007392, filed on Jan. 14, 2004, and Japanese Patent Application No. and 2004-158917, filed on May 28, 2004, all of which are incorporated herein by reference in their entireties.
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to a food containing glycine and use thereof.
  • 2. Discussion of the Background
  • Glycine is a non-essential amino acid having the simplest structure of CH2(NH2)COOH. Glycine is an amino acid approved as a food additive and contained in many foods. For example, beverages contain glycine at a maximum content of about 50 mg/100 ml for the preservation of quality. In addition, glycine is also contained in fish cake products such as steamed fish paste and the like. As a known function of glycine, its intake at 0.1 g per day increases memory and attention (see, File. S. E. et al., Journal of Clinical Psychopharmacology. US, 1999, vol. 19, No. 6, pp. 506-512). Furthermore, addition of glycine as an antispoilage agent for food together with maltose is known (see, JP-B-2-72853), in which case the amount of glycine to be added is, for example, about 0.3% (W/W).
  • SUMMARY OF THE INVENTION
  • Accordingly, it is one object of the present invention to provide novel glycine-containing foods of an unprecedented type, and foods having a new function based on glycine.
  • These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that the intake of a given amount or more of glycine can express several unconventional new functions.
  • Thus, the present invention provides:
  • (1) A food of the type based on unit of intake per serving, which contains glycine or a substance that can be hydrolyzed to give glycine, in an amount equivalent to not less than 0.5 g of glycine per serving.
  • (2) The food of the above-mentioned (1), wherein the content of an amino acid other than glycine or a substance that can be hydrolyzed to give an amino acid other than glycine is equivalent to not more than 5 g of an amino acid other than glycine per serving.
  • (3) The food of the above-mentioned (1) or (2), wherein the glycine or the substance that can be hydrolyzed to give glycine is a powder or a granule.
  • (4) The food of the above-mentioned (1) or (2), wherein the glycine or the substance that can be hydrolyzed to give glycine is slurry.
  • (5) The food of any of the above-mentioned (1)-(4), wherein the food is a beverage.
  • (6) The food of any of the above-mentioned (1)-(4), wherein the food is a confectionery.
  • (7) The food of any of the above-mentioned (l)-(4),-wherein the food is a jelly, pudding or yoghurt.
  • (8) The food of the above-mentioned (1) or (2), which is used for masking a flavor of a food material itself or a flavor imparted by food processing.
  • (9) A food for improving a deep sleep disorder, which contains glycine or a substance that can be hydrolyzed to give glycine.
  • (10) A food for improving bowel movements, which contains glycine or a substance that can be hydrolyzed to give glycine.
  • (11) A method of masking a flavor of a food material itself or a flavor imparted by food processing, which comprises adding 0.15-100% by weight of glycine relative to the food as a whole.
  • (12) A method of improving a deep sleep disorder, which comprises taking a food containing glycine or a substance that can be hydrolyzed to give glycine.
  • (13) A method of improving bowel movements, which comprises taking a food containing glycine or a substance that can be hydrolyzed to give glycine.
  • (14) Use of a food containing glycine or a substance that can be hydrolyzed to give glycine for improving a deep sleep disorder.
  • (15) Use of a food containing glycine or a substance that can be hydrolyzed to give glycine for improving bowel movements.
  • (16) The food of the above-mentioned (9), which has a designation that the food is used for improving a deep sleep disorder.
  • (17) The food of the above-mentioned (10), which has a designation that the food is used for improving bowel movements.
  • (18) A commercial package comprising a food containing glycine or a substance that can be hydrolyzed to give glycine, and a written matter containing an explanation relating to use thereof for masking a flavor of a food material itself or a flavor imparted by food processing.
  • (19) A commercial package comprising a food containing glycine or a substance that can be hydrolyzed to give glycine, and a written matter containing an explanation relating to use thereof for improving a deep sleep disorder.
  • (20) A commercial package comprising a food containing glycine or a substance that can be hydrolyzed to give glycine, and a written matter containing an explanation relating to use thereof for improving bowel movements.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • A more complete appreciation of the invention and many of the attendant advantages thereof will be readily obtained as the same become better understood by reference to the following detailed description when considered in connection with the accompanying drawings, wherein:
  • FIG. 1 is shows glycine intake and sleep hours during a trip to the East Coast, USA, by the test participant (Experimental Example 2); and
  • FIG. 2 is a graph showing the relationship between the lapse of time after glycine administration and R-R interval in a test using beagles (Experimental Example 7).
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The embodiment of the present invention is described in the following.
  • The subject matter of the present invention relates to the novel use of glycine and a food suitable for the use thereof. As mentioned above, glycine is an amino acid having the structure of CH2(NH2)COOH. The “substance that can be hydrolyzed to give glycine” is a substance that affords glycine by hydrolysis (particularly hydrolysis in vivo). Representative examples thereof include proteins and peptides having glycine as a constituent unit. A substance that affords glycine by hydrolysis is expected to provide the same effect as that achieved by direct glycine intake, as a result of generation of glycine due to hydrolysis in the body after the intake.
  • The food of the type based on unit of intake per serving in the present invention contains glycine or a substance that can be hydrolyzed to give glycine in an amount equivalent to not less than 0.5 g of glycine per serving. Since such a food permits easy intake of a large amount of glycine, it allows enjoyment of effects provided by the below-mentioned novel action.
  • The “food of the type based on unit of intake per serving” includes foods having a predetermined amount of intake per serving. In the present specification, food is a concept broadly encompassing those that can be taken orally (excluding pharmaceutical products), and includes what is called “foods”, as well as beverages, health aid foods, healthcare functional foods, supplements, and the like. The unit of intake per serving in the case of, for example, beverage, candy, chewing gum, jelly, pudding, yoghurt and the like, is a pack, a packing, a bottle and the like that define a given amount, and that in the case of a granular, powdery or slurry food is a packing and the like that define a given amount, or a container and the like that indicate the amount of intake per serving.
  • Being “equivalent to glycine” in relation to the content of glycine or a substance that can be hydrolyzed to give glycine in a food means that note is taken of the weight of glycine when glycine itself is contained, and when a substance that can be hydrolyzed to give glycine is contained, note is taken of the weight of glycine when the substance that can be hydrolyzed to give glycine has been entirely converted to glycine. When a food contains both glycine and a substance that can be hydrolyzed to give glycine, note is taken of the total weight of glycine and the substance that can be hydrolyzed to give glycine after complete conversion to glycine by hydrolysis.
  • The content of glycine or a substance that can be hydrolyzed to give glycine per serving is not less than 0.5 g, preferably not less than 1.0 g, more preferably not less than 1.5 g, when converted to the amount of glycine, in view of ease of addition to the food and the effect of the addition. In addition, the above-mentioned content is preferably not more than 100 g, more preferably not more than 60 g, from eating experience based on known findings (see, Evins A. E. et al., American Journal of Psychiatry, US, May 2000, vol. 157, No. 5, pp. 826-828) and ease of packing and intake.
  • The present inventors have also found that the presence of a large amount of one or more amino acids other than glycine in the above-mentioned food tends to prevent the benefit of the below-mentioned effects. Therefore, the total content of any amino acids other than glycine or a substance that can be hydrolyzed to give an amino acid other than glycine is preferably equivalent to not more than 5 g of the amino acids other than glycine per serving. When the total amount of any amino acids other than glycine and a substance that can be hydrolyzed to give an amino acid other than glycine exceeds 5 g in the above-mentioned food containing glycine at a lowest level permitting functional expression, the function of glycine in the present invention is suppressed.
  • While the lower limit of the content of any amino acids other than glycine or a substance that can be hydrolyzed to give an amino acid other than glycine is not particularly defined, for example, 50 mg per serving of an amino acid other than glycine can be mentioned, with preference given to substantial absence.
  • The amino acid other than glycine refers to amino acids other than the above-mentioned glycine. As used herein, by the “amino acid” is meant an organic compound having both an amino group (—NH2) and a carboxyl group (—COOH). The “substance that can be hydrolyzed to give an amino acid other than glycine” is a substance affording an organic compound (except for glycine) having both an amino group and a carboxyl group by hydrolysis (particularly hydrolysis in vivo), and typical examples include proteins and peptides having an amino acid other than glycine as a constituent element can be mentioned.
  • Being “equivalent to an amino acid other than glycine” in relation to the content of an amino acid other than glycine or a substance that can be hydrolyzed to give an amino acid other than glycine in a food means that note is taken of the total of the weight of the amino acid other than glycine and the weight of the amino acid other than glycine, assuming that the substance that can be hydrolyzed to give an amino acid other than glycine has become an amino acid other than glycine by hydrolysis.
  • The shape or form of the glycine or a substance that can be hydrolyzed to give glycine contained in a food is not particularly limited and may be a powder or granule, as well as slurry, tablet, capsule, solution, gel, or emulsion. Of these, granules and powder are preferable for portability and ease of packing. In addition, solution, gel and slurry are also preferable because of the ease of intake.
  • The “slurry” glycine contained in food means a state where solid glycine is suspended in a liquid media. A part of glycine may be dissolved in the above-mentioned media.
  • For example, when the food is what is called a health food, not less than 0.5 g of granular glycine may be packed in an intake unit amount and the like. When the food is a healthy drink, for example, a drink containing not less than 0.5 g of glycine in a suspension or solution is placed in a bottle etc. sized for one meal or serving.
  • The type of food is not particularly limited and application to various foods is possible. Since glycine has a high solubility in water and has preferable sweetness, it can be suitably applied to beverages, confectioneries, jellies, puddings, and yoghurt. Beverages may be served in a bottle, a can, a paper pack and the like in the form of a solution, a suspension and the like, or may be extracted or dissolved for drinking like tea, coffee, powder beverage and the like. As used herein, by confectionery is meant favorite food taken besides meals, such as sweets and the like (e.g., candy, chewing gum, tablet and the like).
  • As the animals other than human to be administered to, mammals such as domestic animal, fowl and the like, experimental animals and the like can be mentioned. The mode of administration to animals other than human may be as an addition to a diet.
  • The invention relating to the novel use of glycine is explained in the following. The novel use of the present invention refers to the use as food flavoring, arousal during sleep and early-morning awakening suppressing food, deep sleep disorder improving food or bowel movement improving food.
  • Food Flavoring:
  • Conventionally, amino acids have been generally used as a reaction flavor under special conditions of industrial environment at high temperature. The present inventors have found that a preferable flavor can be produced upon reaction with sugars contained in the food under conditions that can be generally produced at home, such as addition of boiled water to glycine and the like. In addition, they have found that glycine can be used for masking of undesirable flavor in the food.
  • The food flavoring in the present invention is a concept expressing a substance that adds flavor to a food material having almost no flavor, enforcing the flavor lost during production of food, masking an unpreferable flavor which a food material itself has or which is produced during processing.
  • For use as a food flavoring, glycine only needs to be added to a food. The glycine content can be appropriately determined according to the amount of the flavor to be added and the level of masking to be performed. In the case of a food of the type based on the unit of intake per serving, glycine is added in an amount of preferably 0.5 to 100 g, more preferably 1.0 to 60 g, per serving. In addition, the weight of glycine in the whole food is preferably 0.15 to 100 wt %, more preferably 0.3 to 98 wt %, in consideration of solubility, preferable taste, and effectiveness of flavor and masking. A preferable mode of use for this purpose is, for example, allowing reaction with sugars by heating, such as addition of boiling water and the like. In this case, as the sugars to be reacted, sucrose, fructose, glucose, dextrin, maltose and the like can be mentioned.
  • The present invention also encompasses a method of masking a flavor of a food material itself or a flavor imparted by food processing, which comprises adding glycine in a proportion of 0.15 to 100% by weight, preferably 0.3 to 98 wt %, of the whole food.
  • The “unpreferable flavor” in a food for which glycine is used for masking includes flavors of medicinal plants used for crude drugs and Chinese herbal medicines, yacon, Eucommia ulmoides, and Puer contained in general health food and the like, plant extracts such as Houttuynia cordata used for folk remedies and the like, and herbs generally taken as herb or extracted for drinking.
  • Deep Sleep Disorder Improving Food:
  • Another aspect of the present invention is use of a food containing glycine (or a substance that can be hydrolyzed to give glycine) as a deep sleep disorder improving food.
  • As used herein, by the term “deep sleep disorder” is meant a condition lacking satisfaction from deep sleep on awakening, or a condition of shortage of sleep, or a condition lacking satisfaction in various aspects expected to be afforded by a suitable sleep. For example, such conditions includes shallow sleep, difficult shift to slow wave sleep indicating profound sleep after sleep onset, interrupted sleep, failure to get up at expected time and insufficient sleep hours, and is considered to often occur in an unsuitable sleep environment, in the presence of mental or physical stress, after intake of an ingredient having an awakening effect such as caffeine and the like before bedtime, at the time of excessive drinking, irregular sleep cycles and disturbed biological rhythm, as well as in a time lag environment. It is generally known that sleep plays a role of resting the body, as well as more positively relieving physical and mental fatigue, organizing the memory, and particularly in deep sleep, controlling growth and metabolism balance in the body by the secretion of growth hormone, etc. Therefore, when physical or mental conditions are not improved, fatigue remains, enthusiasm for life is diminished, oversleep occurs the next day, feel lethargic, feel shortage of sleep hours, or headaches occurs after sleeping due to a deep sleep disorder, improvement of these (improvement of deep sleep disorder) is expected to result in, for example, improved physical or mental conditions as shown by decreased lassitude, pleasant awakening on rising and the like, and realization of deep sleep, realization of fine sleep, which in turn increases willingness for life, concentration and the like. In addition, irregular work accompanying shift work and the like, jet lag and the like can also cause a deep sleep disorder, and improvement of these is expected to increase concentration during waking time, prevent oversleep during the daytime, decrease lassitude, and increase willingness to work. A deep sleep disorder improving food is effective not only for improving the above-mentioned deep sleep disorder but also allowing the inherent role of sleep to be fulfilled by improving the quality of sleep. Such a role includes, for example, affording the feeling of being refreshed on rising, decreasing lassitude, preventing tendency of oversleeping during the daytime and the like. A deep sleep disorder improving food can improve the above-mentioned deep sleep disorders. The concept represented by what is called a “sleep disorder” and “insomnia” is also included in the concept of the aforementioned “deep sleep disorder”.
  • The food of the present invention as a deep sleep disorder improving food contains glycine or a substance that can be hydrolyzed to give glycine. The amount of intake of the aforementioned food for this purpose is preferably 0.00625 to 2.5 g/kg/day, more preferably 0.125 to 1.5 g/kg/day (daily intake per 1 kg of body weight), in an amount equivalent to glycine. The term “equivalent to glycine” has the same meaning as mentioned above. An amount not less than the lower limit of the aforementioned numerical range is sufficient to afford the aforementioned effect. When the amount of intake is increased, the intake tends to be come difficult, and the cost becomes high. A food of the aforementioned type based on the unit of intake per serving facilitates control of the amount of intake of glycine.
  • By the aforementioned effect relating to sleep, suppression of sleepiness during the daytime, particularly, enhanced quality of sleep in an environment associated with time difference such as jet lag and the like is expected. Life nowadays sometimes makes it difficult to ensure regular sleep because of the shift of life hours, rotation work and the like. In an environment of inconsistent life time pattern as the above, the quality of life can be improved by increasing the realization of deep sleep on waking and less sleepiness during daytime. While the effect of glycine as mentioned above is assumed to be related to several mechanisms, an action on the sympathetic and parasympathetic nervous system is considered to be particularly significant. The results in a test involving measurement of electrocardiogram of experimental animals indicate that administration of glycine dominantly acts on the parasympathetic nervous system. It is said that the present-day life tends to be sympathetic dominant due to mental stress and the like. Glycine is considered to induce shift to slow wave sleep (deep sleep), improves the quality of sleep during sleep hours, appropriately controls visceral activity during sleep and encourages natural sleep by allowing dominant action on parasympathetic that acts opposite to sympathetic dominant. When glycine is taken for such use relating to sleep, it is most suitably taken before going to bed.
  • As a related concept of the deep sleep disorder improving food, an arousal during sleep suppressing food and an early-morning awakening suppressing food can be mentioned. As used herein, the term “arousal during sleep” means waking up at night and being unable to go back to sleep for a while thereafter and by the “early-morning awakening” is meant waking up earlier than intended and being unable to go back to sleep again. An arousal during sleep or early-morning awakening suppressing food can improve at least one condition of the above-mentioned arousal during sleep and early-morning awakening.
  • The food of the present invention as an arousal during sleep or early-morning awakening suppressing food contains glycine or a substance that can be hydrolyzed to give glycine. The preferable amount of intake of the aforementioned food for this purpose is the same as that of a deep sleep disorder improving food.
  • Bowel Movement Improving Food:
  • Another embodiment of the present invention is use of a food containing glycine (or a substance that can be hydrolyzed to give glycine) as a bowel movement improving food. As used herein, by the term “bowel movement improving” is meant a food capable of improving abnormal bowel movements (ie., constipation and diarrhea).
  • For use as a bowel movement improving food, a food containing glycine or a substance that can be hydrolyzed to give glycine only needs to be taken. The preferable amount of intake of the aforementioned food for this purpose is the same as that of a deep sleep disorder improving food.
  • Commercial Package:
  • In a package containing the food of the present invention and written material with an explanation relating to the use thereof, the written material is, for example, what is called a package insert describing items relating to use, efficacy, drinking/eating method and the like, and the like.
  • Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.
  • EXAMPLES
  • In the tests in Experimental Examples 1-6, 8, other than the test using experimental animals, all test participants voluntarily took glycine as a food additive based on his or her independent wish as a powder or tablet or upon addition to general food, and made comments by his or her free will, which are summarized in those examples. The tests of Experimental Example 9 and the following were performed by a single-blind or double-blind placebo study upon approval of internal ethical review board and under direction of specialized physician.
  • Experimental Example 1
  • Glycine powder (substantially pure, 2 g) was added to commercially available tea bags of the blend tea shown in Table 1 and the same tea bags without the addition were also prepared. A given amount (150 ml) of hot water was added and the tea was extracted for 1 minute. Five test participants drank the extracted blend tea and commented as to the decrease of flavor by the addition of glycine as compared to non-addition of glycine. The decrease of flavor was taken as an index of the masking effect (see, Table 1). The majority of the test participants confirmed the masking effect in all three kinds of the tested blend tea, and most of them found it to be a preferable masking effect.
    TABLE 1
    Masking effect by addition of 2 g of glycine
    per serving to food (unit: person)
    Masking effect present
    preferable unpreferable
    Added to effect effect No masking effect
    Puer blend tea 1 2 2
    Eucommia ulmoides 4 0 1
    blend tea
    Korean ginseng blend 3 0 2
    tea
  • Experimental Example 2
  • The glycine intake and sleep hours when a Japanese test participant living in Japan (male, 44 years old, body weight 62 kg) traveled to the East Coast, USA, are shown in FIG. 1. In the Figure, glycine (substantially pure tablet glycine containing only excipient and flavor) was taken at the time point marked with an arrow, wherein 1.0 g was taken on “June 20” and “June 21” and 1.5 g was taken on “June 22”-“June 26” and “June 29”. This test participant frequently woke up during sleep in previous similar trips, but as is clear from the results of FIG. 1, administration of glycine reduced or eliminated arousal during sleep.
  • Experimental Example 3
  • Three test participants (test participants A-C, body weight 64-74 kg) who were then visiting the U.S. for 5 days took glycine (1.5 g, substantially pure tablet glycine containing only excipient and flavor) before sleep and evaluated the sleepiness felt from 1 pm to 5 pm the next afternoon in 3 levels as compared to the absence of glycine. The results are summarized in Table 2. All three test participants felt a lower level of sleepiness during the next daytime with the intake of glycine as compared to the absence of glycine.
    TABLE 2
    Reduction of sleepiness during daytime the next day due to the intake
    of glycine in environment with time difference (unit: day)
    Mild Heavy
    No sleepiness sleepiness sleepiness
    test Intake of glycine 2 2 0
    participant A Without intake of 0 0 1
    glycine
    test Intake of glycine 2 1 0
    participant B Without intake of 0 0 2
    glycine
    test Intake of glycine 1 0 0
    participant C Without intake of 0 2 2
    glycine
  • Experimental Example 4
  • The test participant (body weight 45 kg) took, before going to bed, 3 g of glycine directly or upon addition to various foods (see, Table 3). The content (amount based on amino acid) of an amino acid other than glycine or a substance that can be hydrolyzed to give an amino acid other than glycine in these foods was generally 0 to 4 g. As compared to free of glycine intake, easiness of falling asleep and realization of deep sleep upon waking the next morning were recorded and summarized in Table 3. By any form of glycine intake, realization of deep sleep and easiness of falling asleep were improved in most cases.
    TABLE 3
    Improvement of realization of deep sleep and easiness of falling
    asleep by glycine (3 g) intake before going to bed (unit: day)
    Improved Improved
    Days of realization of easiness of
    Food containing glycine testing deep sleep falling asleep
    powder
    3 3 3
    addition to hot milk 4 4 4
    addition to yoghurt 7 7 7
    addition to herb tea 5 5 5
    addition to Japanese tea 10 10 9
    addition to hot water or water 14 14 14
  • Experimental Example 5
  • The test participants (body weight 45-80 kg) took 3 g of glycine (substantially pure glycine granule and powder) as it was, or after dissolving or suspending in water, juice, sport beverage and the like, or after addition to jelly, pudding and the like and then slept, after which they voluntarily commented on the quality of sleep as compared to the absence of intake. Out of 77 participants, 58 participants commented that the quality of sleep was improved, 2 participants commented that the quality was degraded and 17 participants commented that no effect was found. The effects on waking such as freshness on waking and improved realization of deep sleep, as well as the effect on the next day of the intake such as reduced sleepiness during daytime, and the effect after the intake such as reduced snore during sleep were found. Besides the above, the minority of participants commented that the stomach ache was reduced, fatigue did not remain the next morning, the mental stress before examination was reduced, menstrual pain became mild, oversleep ceased, stuffed nose was solved and the like (see, Table 4).
    TABLE 4
    Effect on quality of sleep by glycine (3 g) intake
    (voluntary comments of 77 participants, unit: person)
    Enhancing effect on Degrading
    quality of sleep effect
    Awakening was fresh 24 1
    Sleep was deeper 10 0
    Deep sleep was realized 8 0
    Had no dream 4 0
    Slept well 2 0
    Did not wake up at midnight 6 1
    Fell asleep easily 6 0
    sleepiness during daytime reduced 4 0
    Snoring decreased 19 0
  • Experimental Example 6
  • Two test participants (test participant A (body weight 52 kg), B (body weight 45 kg)) took or did not take, before going to bed, glycine (substantially pure tablet glycine containing only excipient and flavor) of the type shown in Table 5. Table 5 reports the bowel movements on the next morning and the corresponding number of days. When glycine was taken before going to bed, the bowel movements in the next morning increased. When taken together with yoghurt, the bowel movements were also improved.
    TABLE 5
    Improved bowel movements by glycine intake (unit: day)
    Presence of No bowel
    bowel movement movement
    test tablet intake (1 g) 10 2
    participant A no intake 4 6
    test powder intake (3 g) 7 1
    participant B intake (3 g) with yoghurt 4 0
    only yoghurt 3 2
    no intake 2 3
  • Experimental Example 7
  • Glycine (substantially pure glycine powder) was administered at 0, 30, or 300 mg/kg (0 mg/kg for control, CTRL) to beagles, and using the beagles, the R-R interval in electrocardiogram was measured by a telemetry system as an index of sympathetic activity. The measurement was conducted in the night after glycine administration. From the R-R interval after oral administration of glycine, moreover, sympathetic activity ((low frequency component LF)/(high frequency component HF)) and parasympathetic activity (high frequency component HF) were examined by power spectrum analysis. FIG. 2 shows the relationship between the lapse of time after administration and the R-R interval. As a result, it was found that the R-R interval increased at 1-4 hr after administration as compared to the control, and the parasympathetic activity was dominant. The results suggest possible involvement of glycine in the relaxation of deep sleep disorders by the relative suppression of sympathetic hyperactivity.
  • Experimental Example 8
  • The test participant A (body weight 45 kg) took glycine (substantially pure powder) in an amount shown in Table 6 before going to bed by dissolving same in water, and recorded the level of realization of deep sleep. When the realization of deep sleep increased than usual, “+” was marked, when the realization of deep sleep was almost the same as usual, “±” was marked and when it became worse, “−” was marked. The results are shown in Table 6.
    TABLE 6
    Amount of intake (in teaspoon) ¼ ½ 1/1
    General amount (g) 0.6 1.2 2.5
    Realization of deep sleep + + +
  • Experimental Example 9
  • A double-blind crossover test aiming at confirmation of the effect of glycine on sleep was performed with 15 female adults (20s -50s, body weight 46-58 kg). The test participants took glycine (granule containing citric acid and the like) in an amount equivalent to 3 g of glycine 1 hr before bedtime, and reduced maltose containing components other than glycine (citric acid and the like) and adjusted to an almost indistinguishable taste was used as a placebo. For the test, glycine and placebo were each taken for 4 days with an interval of a 3 day non-intake period, totaling 2 weeks.
  • (1) As a result of examination using self recording questionnaire for the evaluation of sleep condition, the test participants of 32 years old or older (6 out of 15 participants, body weight 46-58 kg) significantly showed an effect of improving physical conditions on waking (good physical shape, lethargic feeling, heavy-headed feeling and the like) and mental conditions on waking (refreshed feeling, sick feeling and the like), and the test participant having problems regarding sleep (7 out of 15 participants, body weight 46-58 kg) who marked 9 points or more in the Pittsburgh Sleep Quality Index (PSQI) significantly showed an effect of improving mental conditions on waking. The results are shown in Table 7.
    TABLE 7
    Improvement of physical and mental conditions on waking
    by glycine intake (unit: person)
    Comparison with 32 years old PSQI not less
    evaluation item placebo or older than 9
    physical condition on improved 5 5
    waking no change 1 1
    worsened 0 1
    mental condition on improved 5 5
    waking no change 1 2
    worsened 0 0
  • (2) As a result of examination using self recording questionnaire for the evaluation of lassitude on waking, a tendency of reducing lassitude on waking was observed. The results are shown in Table 8. In the Table, the values of glycine and placebo show the number of test participants who showed a decrease of lassitude (decreased total point) or increase (increased total point) as compared to placebo intake, in the total point of 4 days of 10 questions (each 3 levels of 0, 1, 2 points) evaluating the lassitude on waking in a SAM lassitude check list. In the Table, the number of test participants who showed difference by 1 point or more (effective) in the total points and who showed difference by 4 points or more (remarkably effective) are shown.
    TABLE 8
    Effect of reducing lassitude on waking by glycine intake
    remarkably
    effective effective
    Reduction of lassitude 11 7
    (participants)
    No change (participants) 1 6
    Increase of lassitude 3 2
    (participants)
  • (3) As a result of examination using self recording questionnaire for the evaluation of sleep condition, the test participants of 32 years old or older showed significant effect of improving the depth of sleep. The results are shown in Table 9. In the Table, the values of glycine and placebo show the test participant average of the points of evaluation in 8 levels in the sleep questionnaire “depth of sleep”. A greater numerical value indicates that the test participant felt deeper sleep. In addition, the p value is a statistical value showing the probability when the difference between glycine and placebo was hypothesized to be null. Particularly, this value of 0.05 or below is considered to indicate a significant difference.
    TABLE 9
    Effect of improving depth of sleep by glycine intake
    glycine placebo P value
    Sleep questionnaire “depth 4.88 4.13 0.042
    of sleep”
  • (4) At the end of each 1 week test period, a question was asked about the soundness of sleep. As a result, 6 out of 15 participants answered that the week of glycine intake was fine and one participant answered that the week of placebo intake was fine. The remaining 8 participants answered that both were the same.
  • (5) As a result of examination using self recording questionnaire for the evaluation of sleep condition, the test participants of 32 years old or older particularly showed an effect of clearing head the next morning. The results are summarized in Table 10.
    TABLE 10
    Effect of clearing head the next morning by
    glycine intake (unit: person)
    Comparison with Number of
    placebo participants
    Effect of clearing effective 5
    head the next no change 1
    morning worsened 0
  • From the above, it has been shown that glycine intake affords deep sleep, and improves lassitude on waking and physical or mental condition. It is assumed that, as a result of the deep sleep, fatigue was eliminated and the condition on waking was improved.
  • Experimental Example 10
  • A double-blind crossover test aiming at confirmation of the effect of glycine on sleep was performed with 14 male adults (body weight 64-112.5 kg, average 81.2 kg) concerned about snoring and apnea condition during sleep. The test participants took glycine (granules containing citric acid and the like) in an amount equivalent to 3 g of glycine 1 hr before bedtime, and reduced maltose containing components other than glycine (citric acid and the like) and adjusted to an almost indistinguishable taste was used as a placebo.
  • (1) For the evaluation of sleep condition, overnight polysomnography was used for the measurement. As a result, significant difference was not observed in the time from lights-out to sleep onset, but the time from the lights-out to slow wave sleep considered to represent deep sleep was shortened and extension of the slow wave sleep in the early stage of sleep onset was confirmed.
  • In addition, the sleep condition of the night before was examined on waking using the sleep questionnaire. As a result, high marks were obtained for the item of “depth of sleep”. This suggests that the glycine intake facilitated deep sleep. The results are summarized in Table 11. The slow wave sleep (%) in early stage of sleep onset in the Table shows a test participant average of the ratio of slow wave sleep to the early stage (1 hr) of sleep onset.
  • In the OSA sleep questionnaire, a test participant average of the points of 4 levels (0, 11, 21, 32 points) was calculated. A higher point value means the answer of the test participant that the sleep was deeper. The point value with the glycine intake was 16.7, which is higher than the point value 12.3 with placebo intake. This means deeper sleep afforded by the glycine intake.
    TABLE 11
    Effect of facilitating deep sleep by glycine intake
    glycine placebo p value
    lights-out - sleep onset 13.3 16.3 0.322
    (min.)
    lights-out - slow wave 52.2 103.4 0.042
    sleep (min.)
    slow wave sleep (%) in 12.0 6.4 0.020
    sleep onset initial stage
  • (2) The sleep condition of the night before was examined on waking using the OSA sleep questionnaire. As a result, the tendency of less time of dozing off was obtained. It is considered that resistance to sleep onset during bedtime was reduced. In the OSA sleep questionnaire, a test participant average of the points of 4 levels (0, 11, 19, 30 points) was calculated. A higher point value means the answer of the test participant that the time of dozing off was shorter. The point value with glycine intake was 24.9, which is higher than the point value 19.6 with placebo intake. This means that the time of dozing off was shorter with the glycine intake and deep sleep was obtained after the sleep onset.
  • Experimental Example 11
  • Glycine (substantially pure glycine powder) was administered to rats at 0 g/kg and 2 g/kg (0 g/kg for control) and using the rat, spontaneous electroencephalogram and cervix electromyogram were recorded through an electrode placed in the cortex hippocampus, and further, the amount of spontaneous motor activity was measured by an infrared ray monitor. The sleep-wake cycle was analyzed from the electroencephalogram, electromyogram and behavior record (kymogram), and percent occupation of light period and dark period and latency time were calculated. Table 12 shows percent occupation of sleep-wake cycle at every 3 hours, Table 13 shows latency time and Table 14 shows the amount of spontaneous motor activity at 6 hours after administration (all in mean±standard error).
    TABLE 12
    Percent occupation of each sleep - wake cycle (unit: %) after administration
    Lapse of time
    sleep - (hr) after light period dark period
    wake cycle administration control group glycine group control group glycine group
    waking 0-3 44.4 ± 7.1 39.6 ± 6.0 71.6 ± 4.1 67.6 ± 7.9
    stage 4-6 32.4 ± 1.3 20.7 ± 0.8 69.3 ± 1.3 65.6 ± 3.4
    slow wave 0-3 49.6 ± 6.1 54.9 ± 4.9 25.7 ± 3.6 29.2 ± 6.5
    sleep stage 4-6 56.1 ± 1.9 65.9 ± 2.0 28.3 ± 1.4 31.5 ± 2.8
    fast wave 0-3  6.0 ± 1.7  5.5 ± 1.6  2.7 ± 0.9  3.2 ± 1.7
    sleep stage 4-6 11.5 ± 1.3 13.4 ± 2.1  2.4 ± 0.4  3.0 ± 0.7
  • TABLE 13
    Latency time (unit: min) of each sleep stage after administration
    Light period Dark period
    sleep - control glycine control glycine
    wake cycle group group group group
    slow wave 22.1 ± 9 8.5 ± 1.2 73.0 ± 13.4 78.6 ± 22.8
    sleep stage
    fast wave 20.4 ± 6 20.9 ± 3.4  99.6 ± 34.6 118.2 ± 28.3 
    sleep stage
  • TABLE 14
    Amount (unit: count) of spontaneous motor activity at 6 hr
    after administration
    control group glycine group
    light period 4193 ± 777 2316 ± 295
    dark period 21519 ± 2997 19464 ± 2765

    When glycine was administered during the daytime, the proportion of waking stage became less as compared to the control. As to the detail of the sleep stage, both the slow wave sleep stage and the fast wave sleep stage slightly increased. In contrast, the dark period did not show any effect. As shown in Table 13, for each latency time of the sleep stage, namely, the time before the first emergence of sleep after administration, the slow wave sleep stage latency time was shortened in the glycine administration group and it was suggested that a deep sleep might have been easily induced by glycine.
  • As shown in Table 14, moreover, the amount of spontaneous motor activity during the light period decreased in the glycine administration group, but it did not show any difference in the dark period. From the above results, it was shown that glycine encourages natural sleep without markedly changing the constitution of sleep only in the light period, which is the inherent resting stage of rats.
  • Experimental Example 12
  • A single-blind crossover study aimed at confirmation of the effect of glycine on sleep was performed with 7 male adults (30s -40s, body weight 62-79 kg). The test participants took glycine (granule containing citric acid and the like) in an amount equivalent to 3 g of glycine 30 min before bedtime, and reduced maltose containing components other than glycine (citric acid and the like) and adjusted to an almost indistinguishable taste was used as a placebo. The sleep hours on the day of administration was limited to about 75% (5-6.5 hr) of comfortable sleep hours each test participant voluntarily notified, and a nap was prohibited until the end of the administration. For the test, glycine and placebo were each taken for 3 days with an interval of a 14-21 day non-intake period, totaling 4-5 weeks. Of the 3 days, the following investigation and measurement were performed at 10 o'clock, 14 o'clock and 18 o'clock of the next day of the first day of the intake.
  • (1) As a result of examination using self recording questionnaire for the evaluation of physical and mental conditions, an effect of significantly improving physical and mental conditions such as daytime lassitude and sleepiness was observed, as shown in Table 15. In the Table, the values of glycine and placebo regarding “lassitude” show the total points of 10 questions (each 3 levels of 0, 1, 2 points) evaluating the lassitude in a SAM lassitude check list. A greater value means that greater lassitude was felt. The values of glycine and placebo regarding “sleepiness” show the distance from the left end, wherein the left end of a 100 mm line is “no sleepiness” and the right end is “very sleepy”, and the condition from the feeling at that time was marked on the line. A greater value means that the sleepiness was intense. In addition, the p value is a statistical value showing the probability when the difference between glycine and placebo was hypothesized to be null. Particularly, this value of 0.05 or below is considered to indicate a significant difference. It was shown that glycine improved physical and mental conditions such as daytime lassitude and sleepiness of the next day by improving the sleep conditions.
  • (2) To evaluate the cognitive and psychomotor function as a reflection of the quality of sleep, an operation efficiency test using a computer was performed. The results are shown in Table 16. As a three kind discrimination response task, a task of responding to only one predetermined kind from randomly designed three kinds of graphics on the screen was given. As a result, increase in the percentage of correct answer, shortened response time, and decrease in lapse (number of response where reaction time was 500 msec or longer) were significantly observed. From these results, it was shown that glycine increased psychomotor function during the next daytime and improved operation efficiency and concentration by increasing the quality of sleep.
    TABLE 15
    Effect of decreasing lassitude of next daytime by glycine intake
    Placebo (mean ± Glycine (mean ±
    standard error) standard error) p value
    lassitude  9.0 ± 0.68  7.0 ± 0.74 0.025
    sleepiness 50.7 ± 4.39 38.1 ± 4.47 0.042
  • TABLE 16
    Effect of improving operation efficiency and concentration of next
    daytime by glycine intake
    Placebo (mean ± Glycine (mean ±
    standard error) standard error) p value
    percentage of 95.6 ± 5.20 98.4 ± 1.16 0.043
    correct answer
    (%)
    Response time 0.393 ± 0.025 0.366 ± 0.021 0.028
    (sec)
    Lapse (times) 2.67 ± 3.06 1.19 ± 1.69 0.017
  • INDUSTRIAL APPLICABILITY
  • The food of the present invention can provide a masking effect of an unpreferable flavor, a deep sleep disorder improving effect, such as an arousal during sleep suppressing effect and an early-morning awakening suppressing effect, a bowel movement improving effect and the like. A food of the type based on the unit intake of the present invention can easily enjoy the effect afforded by the above-mentioned action.
  • Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.
  • All patents and other references mentioned above are incorporated in full herein by this reference, the same as if set forth at length.

Claims (20)

1. A food of the type based on unit of intake per serving, which comprises glycine or a substance that can be hydrolyzed to give glycine, in an amount equivalent to not less than 0.5 g of glycine per serving.
2. The food of claim 1, wherein said food comprises an amino acid other than glycine or a substance that can be hydrolyzed to give an amino acid other than glycine in an amount which is equivalent to not more than 5 g of said amino acid other than glycine per serving.
3. The food of claim 1, wherein said glycine or said substance that can be hydrolyzed to give glycine is a powder or a granule.
4. The food of claim 1, wherein said glycine or said substance that can be hydrolyzed to give glycine is slurry.
5. The food of claim 1, wherein said food is a beverage.
6. The food of claim 1, wherein said food is a confectionery.
7. The food of claim 1, wherein said food is a jelly, pudding or yoghurt.
8. The food of claim 1, which is used for masking a flavor of a food material itself or a flavor imparted by food processing.
9. A food for improving a deep sleep disorder, which contains glycine or a substance that can be hydrolyzed to give glycine.
10. A food for improving bowel movements, which contains glycine or a substance that can be hydrolyzed to give glycine.
11. A method of masking a flavor of a food material itself or a flavor imparted by food processing, which comprises adding to said food 0.15 to 100% by weight of glycine based on the total weight of said food.
12. A method of improving a deep sleep disorder, which comprises taking a food containing glycine or a substance that can be hydrolyzed to give glycine.
13. A method of improving bowel movements, which comprises taking a food containing glycine or a substance that can be hydrolyzed to give glycine.
14. The method of claim 12, which comprises taking said food containing glycine or a substance that can be hydrolyzed to give glycine in an amount equivalent to 0.00625 to 2.5 g/kg/day of glycine.
15. The method of claim 13, which comprises taking said food containing glycine or a substance that can be hydrolyzed to give glycine in an amount equivalent to 0.00625 to 2.5 g/kg/day of glycine.
16. The food of claim 9, which has a designation that the food is used for improving a deep sleep disorder.
17. The food of claim 10, which has a designation that the food is used for improving bowel movements.
18. A commercial package comprising a food containing glycine or a substance that can be hydrolyzed to give glycine, and written material containing an explanation relating to use of said food for masking a flavor of a food material itself or a flavor imparted by food processing.
19. A commercial package comprising a food containing glycine or a substance that can be hydrolyzed to give glycine, and written material containing an explanation relating to use of said food for improving a deep sleep disorder.
20. A commercial package comprising a food containing glycine or a substance that can be hydrolyzed to give glycine, and written material containing an explanation relating to use of said food for improving bowel movements.
US11/165,200 2004-01-14 2005-06-24 Food containing glycine and use thereof Active 2029-05-30 US10561629B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP007392/2004 2004-01-14
JP2004-007392 2004-01-14
JP2004007392 2004-01-14
JP158917/2004 2004-05-28
JP2004-158917 2004-05-28
JP2004158917 2004-05-28
PCT/JP2004/019771 WO2005067738A1 (en) 2004-01-14 2004-12-24 Glycine-containing food and use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/001977 Continuation-In-Part WO2004077564A1 (en) 2003-02-26 2004-02-20 Thin-film capacitative element and electronic circuit or electronic equipment including the same

Publications (2)

Publication Number Publication Date
US20060003083A1 true US20060003083A1 (en) 2006-01-05
US10561629B2 US10561629B2 (en) 2020-02-18

Family

ID=34797738

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/165,200 Active 2029-05-30 US10561629B2 (en) 2004-01-14 2005-06-24 Food containing glycine and use thereof

Country Status (6)

Country Link
US (1) US10561629B2 (en)
EP (1) EP1609375B1 (en)
JP (5) JP4913410B2 (en)
KR (2) KR20120120423A (en)
CN (2) CN102160650B (en)
WO (1) WO2005067738A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160158382A1 (en) * 2014-12-09 2016-06-09 Nikolay LEONIDOV Agent for the treatment and prevention of sleep disorders
US20170239441A1 (en) * 2016-02-24 2017-08-24 Incept, Llc Method of making an enhanced flexibility neurovascular catheter
US11019548B2 (en) 2017-11-24 2021-05-25 Samsung Electronics Co., Ltd. Electronic device and communication method thereof
EP3825314A4 (en) * 2018-07-19 2022-04-06 Medshine Discovery Inc. Azaindole derivative and use thereof as fgfr and c-met inhibitor

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101081757B1 (en) * 2003-05-19 2011-11-10 아지노모토 가부시키가이샤 Preventives/remedies for snore or respiratory disturbances during sleep
CN102160650B (en) * 2004-01-14 2012-12-26 味之素株式会社 Food containing glycine and use thereof
JP2006333872A (en) * 2004-01-14 2006-12-14 Ajinomoto Co Inc Food containing glycine and use thereof
JP5110314B2 (en) * 2006-04-28 2012-12-26 ライオン株式会社 Sleep improving composition and sleep improving agent
JP2008150352A (en) * 2006-12-15 2008-07-03 Mg Seiyaku Kk Sleep-improving agent composition
CN105592725A (en) * 2013-10-09 2016-05-18 味之素株式会社 Foodstuff containing histidine and application therefor
WO2020080394A1 (en) * 2018-10-16 2020-04-23 日本ケミファ株式会社 Agent for improving quality of sleep
JP2020172459A (en) * 2019-04-09 2020-10-22 国立大学法人 新潟大学 AGENT FOR INHIBITING AGGLOMERATION OF AMYLOID β PROTEIN AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE
KR102329246B1 (en) 2019-05-09 2021-11-23 주식회사 엠에이치투 바이오케미칼 Composition of food or pharmacy for inducing sleep of good quality
JP6873291B1 (en) 2020-02-05 2021-05-19 雪印メグミルク株式会社 Sleep-promoting compositions and foods, medicines, feeds containing the compositions
CN115397262A (en) 2020-04-14 2022-11-25 日本化学药品株式会社 Sleep quality improving agent

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4397866A (en) * 1979-05-07 1983-08-09 Massachusetts Institute Of Technology Process for increasing glycine levels in the brain and spinal cord
US4638013A (en) * 1983-11-30 1987-01-20 Boehringer Biochemia Robin S.P.A. Dietetic supplement and prepackaged food in which it is contained, process of preparation and method of administration
US4758439A (en) * 1984-06-11 1988-07-19 Godfrey Science & Design, Inc. Flavor of zinc supplements for oral use
US4980168A (en) * 1989-10-13 1990-12-25 Natrol, Inc. Dietary supplement for children
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5480865A (en) * 1994-02-25 1996-01-02 Parkinson's Charitable Trust Nutritional composition
US5643954A (en) * 1992-01-10 1997-07-01 Komissarova; Irina Alexeevna Method of preventing and alleviating stress in a healthy mammal in need thereof
US6416795B1 (en) * 2000-09-20 2002-07-09 Byung Hak Choi Herbal extract composition for stress prevention and treatment
US6461634B1 (en) * 1999-08-20 2002-10-08 Edward Marshall Food-based delivery of HGH-stimulating and other nutritional supplements

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1052772A (en) * 1974-11-14 1979-04-17 Irving Goodman Peptides for control of intestinal motility
JPH0272853A (en) * 1988-01-07 1990-03-13 Hiroe Ogawa Inhibitor against change of quality for food and prevention of change of quality of food
JP3246738B2 (en) * 1990-11-30 2002-01-15 ロート製薬株式会社 Saponin and amino acid-containing composition
CN1078359A (en) * 1993-01-20 1993-11-17 中德联合研究院 A kind of food for invigorating intelligence and brain and production method thereof
CN1110112A (en) * 1994-04-11 1995-10-18 贾增申 Amino acid solid drink and preparation method thereof
JP2001224334A (en) * 2000-02-16 2001-08-21 Ajinomoto Co Inc Beauty food containing amino acid
JP3550559B2 (en) 2001-10-18 2004-08-04 アサヒ飲料株式会社 Glycine-containing beverages
DE10221403A1 (en) * 2002-05-14 2003-12-04 Kyberg Pharma Vertriebs Gmbh & Dietetic and/or pharmaceutical composition based on free aminoacids, vitamins and minerals, having specific aminoacid profile providing good immunostimulant effect
RU2220712C1 (en) * 2002-07-18 2004-01-10 ЗАО "НПО ПЦ Биофизика" Agent and set for normalization of functional disorders arising in preclimacteric and climacteric period
KR101081757B1 (en) 2003-05-19 2011-11-10 아지노모토 가부시키가이샤 Preventives/remedies for snore or respiratory disturbances during sleep
CN100448453C (en) * 2003-05-22 2009-01-07 努特里奇亚有限公司 A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein
CN102160650B (en) * 2004-01-14 2012-12-26 味之素株式会社 Food containing glycine and use thereof
JP2006333872A (en) * 2004-01-14 2006-12-14 Ajinomoto Co Inc Food containing glycine and use thereof
JP2006169221A (en) * 2004-12-13 2006-06-29 Crescendo Corporation Sleeping supplement

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4397866A (en) * 1979-05-07 1983-08-09 Massachusetts Institute Of Technology Process for increasing glycine levels in the brain and spinal cord
US4638013A (en) * 1983-11-30 1987-01-20 Boehringer Biochemia Robin S.P.A. Dietetic supplement and prepackaged food in which it is contained, process of preparation and method of administration
US4758439A (en) * 1984-06-11 1988-07-19 Godfrey Science & Design, Inc. Flavor of zinc supplements for oral use
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US4980168A (en) * 1989-10-13 1990-12-25 Natrol, Inc. Dietary supplement for children
US5643954A (en) * 1992-01-10 1997-07-01 Komissarova; Irina Alexeevna Method of preventing and alleviating stress in a healthy mammal in need thereof
US5480865A (en) * 1994-02-25 1996-01-02 Parkinson's Charitable Trust Nutritional composition
US6461634B1 (en) * 1999-08-20 2002-10-08 Edward Marshall Food-based delivery of HGH-stimulating and other nutritional supplements
US6416795B1 (en) * 2000-09-20 2002-07-09 Byung Hak Choi Herbal extract composition for stress prevention and treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Blum et al., "Synergy of Ethanol and Putative Nerotransmitters: Glycine and Serine", Science, 176(4032), p 292-294, 1972 *
Carrier et al. J Sleep Res 6, p 230-237, 1997. *
Kryger et al., "Stress-Related Transient Insomnia," Principles and Practice of Sleep Medicine, 3rd ed., Saunders, 2000, pp. 627-628; copied provided by Applicant on March 8, 2010 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160158382A1 (en) * 2014-12-09 2016-06-09 Nikolay LEONIDOV Agent for the treatment and prevention of sleep disorders
US20170239441A1 (en) * 2016-02-24 2017-08-24 Incept, Llc Method of making an enhanced flexibility neurovascular catheter
US11019548B2 (en) 2017-11-24 2021-05-25 Samsung Electronics Co., Ltd. Electronic device and communication method thereof
US11218938B2 (en) 2017-11-24 2022-01-04 Samsung Electronics Co., Ltd. Electronic device and communication method thereof
EP3825314A4 (en) * 2018-07-19 2022-04-06 Medshine Discovery Inc. Azaindole derivative and use thereof as fgfr and c-met inhibitor

Also Published As

Publication number Publication date
JP4913410B2 (en) 2012-04-11
CN1780562A (en) 2006-05-31
KR20060112593A (en) 2006-11-01
US10561629B2 (en) 2020-02-18
KR20120120423A (en) 2012-11-01
JP2013121961A (en) 2013-06-20
JP2015212282A (en) 2015-11-26
KR101214391B1 (en) 2012-12-21
CN102160650B (en) 2012-12-26
WO2005067738A1 (en) 2005-07-28
EP1609375A4 (en) 2006-08-30
JP5976552B2 (en) 2016-08-23
JP6271472B2 (en) 2018-01-31
EP1609375A1 (en) 2005-12-28
JPWO2005067738A1 (en) 2007-07-26
JP5686615B2 (en) 2015-03-18
CN1780562B (en) 2011-04-13
EP1609375B1 (en) 2016-04-13
JP2012211167A (en) 2012-11-01
JP2011093933A (en) 2011-05-12
CN102160650A (en) 2011-08-24

Similar Documents

Publication Publication Date Title
US10561629B2 (en) Food containing glycine and use thereof
JP4951162B2 (en) Sleep improvement composition
JPWO2009145363A1 (en) A composition having an antidepressant-like action or a fatigue recovery action by improving sleep, comprising a hot water extract of a forget-me-not plant
WO2013051728A1 (en) Agent for improving quality of sleep
JP6100692B2 (en) Sleep quality improver
CN111802644A (en) Food composition for improving sleep
CN106470691B (en) Compositions comprising cinnamaldehyde and zinc and methods of using such compositions
JP2006333872A (en) Food containing glycine and use thereof
JP2006028051A (en) Ameliorant for exhausted feeling at time of rising, composition for ameliorating exhausted feeling at time of rising, and food and beverage for ameliorating exhausted feeling at time of rising, containing them
JP3240345B2 (en) Oral hypnotics, hypnotic foods and drinks
KR20090045721A (en) Compositions for improving sleep disturbance
JPH1025246A (en) Oral hypnotic agent, hypnotic beverage and food, and hypnotic feed
JP2005289948A (en) Sleep improvement composition
JP2019142852A (en) New composition
JP6650852B2 (en) Sleep quality improving agent containing docosahexaenoic acid
JP2015214518A (en) Method for improving quality of sleep and oral composition for improving quality of sleep
Dwivedi et al. CAFEEINE: AN IMPORTANT COMPONENT OF OUR DAILY METABOLISM
JP2015218119A (en) Sleep-improving agent and foods and drinks using the same
JP4435882B2 (en) Alcohol absorption inhibiting composition
JP2006137746A (en) Orexin-inducing composition
CN115397262A (en) Sleep quality improving agent
JP2020018215A (en) Fatigue feeling alleviation agent and food and drink composition for fatigue feeling alleviation
WO2014163152A1 (en) Non-rem sleep-promoting agent, deep sleep-promoting agent and natural sleep-inducing agent
KR20040094717A (en) Composition for preventing hypertension

Legal Events

Date Code Title Description
AS Assignment

Owner name: AJINOMOTO CO., INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOUDA, TOHRU;MORISHIMA, CHIKA;INAGAWA, KENTARO;AND OTHERS;SIGNING DATES FROM 20050728 TO 20050729;REEL/FRAME:017003/0101

Owner name: AJINOMOTO CO., INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOUDA, TOHRU;MORISHIMA, CHIKA;INAGAWA, KENTARO;AND OTHERS;REEL/FRAME:017003/0101;SIGNING DATES FROM 20050728 TO 20050729

STCV Information on status: appeal procedure

Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4